TY - JOUR
T1 - Treatment of chronic inflammatory diseases with biologic agents
T2 - Opportunities and risks for the elderly
AU - Diaz-Borjon, Alejandro
AU - Weyand, Cornelia M.
AU - Goronzy, Jörg J.
N1 - Funding Information:
This work was funded in part by grants from the National Institutes of Health (RO1 AR 42527, RO1 AI 44142, RO1 AR 41974, RO1 AI57266, RO1 AG15043, and RO1 EY 11916). The authors thank Tamela Yeargin for manuscript editing.
PY - 2006/12
Y1 - 2006/12
N2 - The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.
AB - The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.
KW - Autoimmune rheumatic disease
KW - B cells
KW - Biologic agents
KW - Elderly
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=33751515683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751515683&partnerID=8YFLogxK
U2 - 10.1016/j.exger.2006.10.010
DO - 10.1016/j.exger.2006.10.010
M3 - Short survey
C2 - 17125948
AN - SCOPUS:33751515683
SN - 0531-5565
VL - 41
SP - 1250
EP - 1255
JO - Experimental Gerontology
JF - Experimental Gerontology
IS - 12
ER -